Abstract. Oncogenic drivers of osteosarcoma remain controversial due to the complexity of the genomic background of the disease. There are limited novel therapeutic options, and the survival rate of patients with osteosarcoma has not improved in decades. Genomic instability leads to complexity in various pathways, which is potentially revealed at the protein level. Therefore, the present study aimed to identify the mechanisms involved in the oncogenesis of osteosarcoma using proteomics and bioinformatics tools. As clinical specimens from patients are the most relevant disease-related source, expression patterns of proteins in osteosarcoma tissues were compared with soft tissue callus from donors containing high numbers of osteoblastic cells. Two-dimensional electrophoresis and liquid chromatography-tandem mass spectrometry (LC-MS/MS) successfully identified 33 differentially expressed proteins in the osteosarcoma tissues compared with the soft tissue callus. Among these proteins, 29 proteins were significantly upregulated in osteosarcoma. A functionally grouped network of the overexpressed proteins, that was created using the ClueGo and CluePedia applications, demonstrated that the unfolded protein response (UPR) pathway was activated mainly through the activating transcription factor 6 arm in osteosarcoma. The results of proteomics analysis were confirmed by elevated expression of UPR-related chaperone proteins, including 78 kDa glucose-related protein (GRP78), endoplasmin, calreticulin and prelamin-A/C, in the patient-derived primary cells and osteosarcoma cell lines. Furthermore, the expression of GRP78, a master regulator of the UPR, was enhanced in the osteosarcoma tissues of patients that were resistant to double regimen of doxorubicin and a platinum-based drug. The findings of the present study suggest that targeting the UPR pathway may be promising for the treatment of osteosarcoma.

Introduction

Osteosarcoma is an aggressive malignant tumor of bone, which is mainly observed in children and adolescents (1). Up to 70% of patients with osteosarcoma are treated with multimodal therapies that include chemotherapy [such as doxorubicin (DOX), methotrexate and cisplatin] and surgical excision (2,3). However, over the past three decades, survival rates have not substantially improved. Furthermore, there is a lack of effective therapeutic options for patients suffering from a recurrence and metastasis of the disease. The lack of options is mainly due to the complicated etiologies of the disease, which are responsible for an extremely complex genomic organization that results from chromosome aberrations, chromothripsis, kataegis, and genome instability with a high rate of copy number alterations and structural variations (4,5). In addition, accumulating evidence indicates that there are epigenetic changes in osteosarcoma, mainly through histone modifications and DNA methylation (6). This aberrance induces significant alterations in the expression levels of various oncogenic proteins and tumor suppressors in osteosarcoma (7-10). The intricate heterogeneity introduces difficulties for the identification of key oncogene-driven pathways, which may be potential targets for effective treatment of osteosarcoma.

While genomics provide an insight into the molecule profile of cancer, which indicates key players in the tumorigenesis and progression of the disease, proteomics connects the
genomic information with disease phenotypes. Defects at the genomic level affect cellular function and regulation, which are revealed at the protein level. Recent advances in current proteomic techniques and bioinformatics allow detailed and more complete views of biological networks relating to disease.

Cancer patient tissue is an ideal biological specimen for studying disease etiology at the genomic and proteomic levels as it most accurately represents the subject. In addition, the method of fresh freezing is a compatible preservation procedure for subsequent proteomic analysis. Therefore, in the present study, proteomics analysis using freshly frozen biopsy tissues from patients with osteosarcoma was performed. Due to the pathophysiology of osteosarcoma, one of limitations in a proteomics study is that there are no adequate comparable control tissues. To date, the majority of proteomic studies of osteosarcoma tissues have been performed using clinical specimens from patients compared with benign bone tumors (11,12). No consensus representative normal tissues have been defined. In the present study, soft tissue callus was used as a non-cancerous control tissue. Soft callus is formed during the normal fracture repair process primarily from periosteal cells, which are the major source of osteoblasts and chondrocytes (13,14). Bone callus has been demonstrated to contain the highest density of active osteoblasts at 3 months after a fracture, and then the density decreases over time (15). Thus, soft callus is a good source of non-cancerous tissue containing high numbers of osteoblastic cells that can be used as a control in a proteomics study of osteosarcoma.

The aim of the present study was to obtain novel information regarding osteosarcoma mechanisms by studying protein patterns directly from clinical tissues together with bioinformatics tools. The findings suggest disease-relevant pathways that may serve as novel targets for the treatment of osteosarcoma.

Materials and methods

Patients and tissue samples. Chemonaive osteosarcoma tissues were obtained from patients diagnosed and treated at Maharaj Nakorn Chiang Mai Hospital (Chiang Mai, Thailand). Soft tissue callus was collected from donors who were treated at the Trauma Unit, Maharaj Nakorn Chiang Mai Hospital. All tissue samples were freshly frozen and stored at -80°C until use. Patients, or parents in the case of minors, and volunteers gave written consent to be included in the study. This study was approved by the Research Ethics Committee of the Faculty of Medicine, Chiang Mai University (Chiang Mai, Thailand). All clinicopathological parameters were retrieved from hospital records and pathology reports (Table I).

Two-dimensional electrophoresis (2DE) of proteins from osteosarcoma and soft callus tissues. Osteosarcoma and soft callus tissues were lysed in radioimmunoprecipitation assay buffer supplemented with 1% protease inhibitor (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), homogenized and incubated on ice for 30 min. The supernatant was collected by centrifugation at 15,000 x g at 4°C for 20 min. Crude tissue lysates were further prepared for 2DE analysis using a 2-D Clean-Up kit, according to the manufacturer's protocol (GE Healthcare Life Sciences, Uppsala, Sweden). Protein concentration was determined using Bradford assay.

The protein pellets were resuspended in 2D lysis buffer. Individual samples (60 µg protein) were applied by overnight in-gel rehydration of 7 cm pH 3-10 nonlinear gradient IPG strips (GE Healthcare, Chicago, IL, USA). IEF was performed at 7,000 Vh, 55 mA per gel strip using an Ettan IPGphor 3 (GE Healthcare). The IPG strips were equilibrated and separated in 14% SDS-PAGE followed by SYPRO Ruby staining (Thermo Fisher Scientific, Inc., Waltham, MA, USA), as previously described (16). Gels were scanned and visualized using Ettan DIGE Imager (GE Healthcare).

Spot detection and analysis. To minimize contamination by the highly abundant protein present in the tissue samples, the protein spots on the 2DE gels were aligned to human serum protein patterns, as previously reported (17). Major highly abundant proteins, including α and γ Ig heavy chain, serum albumin, hemoglobin β chain, complement factor B and transferrin, were observed in every 2DE gel. The volume of abundant proteins present was subtracted from the total volume of all protein spots on individual gels. The gels were then analyzed using ImageMaster 2D Platinum 7.0 software (GE Healthcare). The relative volume (%) of a spot was used to compare differences in the expression of each protein between the osteosarcoma and soft callus tissues. In addition to strict control of sample preparation and the experimental procedure of the first- and second-dimension separation, statistical analyses were applied in order to minimize experimental variations and increase the reliability and overall reproducibility of the 2DE results. Each gel of the osteosarcoma tissues (4 cases) was independently compared to each gel from the soft tissue callus (4 cases), generating 16 match sets in total. Only spots that were consistently upregulated or downregulated in ≥80% of all match sets and significantly different by ≥1.5-fold (P<0.05, Student's t-test) were subjected to protein identification.

In-gel digestion. The protein spots from the osteosarcoma tissues were excised and subjected to in-gel trypsin digestion, as previously described (16). Briefly, the excised gels were destained with 50% ACN in 0.1 M NH₄HCO₃, reduced with 10 mM DTT, alkylated in 100 mM iodoacetamide and digested with trypsin (Promega Corporation, Madison, WI, USA) at 37°C overnight. The digested peptides were dried and collected for protein identification by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Protein identification by LC-MS/MS. The digested peptides were identified using nanoflow liquid chromatography coupled with nano ESI MS/MS (Q-TOF micro) (both from Waters Corporation, Milford, MA, USA). The MS/MS spectra were processed using MassLynx 4.0 software (Waters Corporation) and converted to PKL files using ProteinLynx 2.2 software (Waters Corporation). Protein identification was performed using the Mascot search engine with NCBIInr version 20130630 sequence and SwissProt databases (http://www.matrixscience.com). The search parameters were set as follows: Peptide mass tolerance, 1.2 Da; MS/MS ion mass tolerance, 0.2 Da; allowance, 1 missed cleavage; enzyme, trypsin; and limit of peptide charges, 1+, 2+ and 3+. Proteins identified with P<0.05 were considered as promising hits. Proteins with a molecular weight and pI consistent with
the spots on the 2DE gels were considered to be positively identified.

**Gene ontology (GO) terms enrichment and pathway analysis.** Functional enrichment analysis of the upregulated proteins in osteosarcoma was performed using WebGestalt (18), ClueGO (version 2.3.3) and CluePedia (version 1.3.3), a plugin for Cytoscape version 3.4, were used for functionally grouped network analysis (19,20).

**Primary cell extraction and characterization.** Primary osteoblastic cells were isolated from bone grafts of patients who had been diagnosed with non-cancerous orthopedic conditions and required the use of autologous bone grafts as substitution procedures. Primary osteoblasts used in this study were derived from a set of bone graft specimens previously reported (6). Primary osteosarcoma cells were extracted from chemo naïve biopsies of patients with osteosarcoma. Extraction, culturing and characterization of the primary cells were performed according to previously described protocols (21). Briefly, the primary cells were isolated by incubating the tissues in 5 mg/ml collagenase type I solution (Gibco; Thermo Fisher Scientific, Inc.) at 37°C for 18 h. The cells were pelleted by centrifugation and cultured in freshly prepared Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) at 37°C in a humidified 5% CO₂ incubator. All primary cells were characterized for doubling time and osteogenicity. Cancer markers, including matrix metalloproteinase (MMP)-9 and collagen type X, were determined by reverse transcription-quantitative polymerase chain reaction, according to a previously described protocol (21).

**Cell culture.** Osteosarcoma and osteoblastic cell lines used in this study include MNNG/HOS (CLS 300289; Cell Lines Service, GmbH, Eppelheim, Germany), U2OS (CLS-300364; Cell Lines Service, GmbH), 143B (CRL-8303; ATCC, Manassas, VA, USA), MG-63 (CRL-1427; ATCC), Saos-2 (HTB-85; ATCC) and normal human osteoblast cell line hFOB1.19 (CRL-11372; ATCC). MNG/HOS was cultured in Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.). MG-63 was cultured in DMEM supplemented with 10% FBS. 143B cells were cultured in DMEM supplemented with 10% FBS and 0.015 mg/ml 5 -bromo-2'-deoxyuridine (Merck KGaA). U2OS, Saos-2 and hFOB1.19 were cultured in F-12 Medium supplemented with 10% FBS. All the cells were maintained at 37°C in humidified 5% CO₂ incubator.

**Western blot analysis and total protein staining.** Crude proteins were extracted from osteosarcoma cells and
tissue samples, as well as osteoblastic cells and soft callus tissues, with RIPA buffer supplemented with 1% protease inhibitor cocktail (Amresco, LLC, Solon, OH, USA). Protein concentration was determined by Bradford assay. Extracted proteins (10-15 μg) were separated in 10% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes (Immobilon-P; EMD Millipore, Billerica, MA, USA). Protein bands on the blots of tissue samples were stained using 0.15% (w/v) Ponceau S dye (Sigma-Aldrich; Merck KGaA) in 1% acetic acid. The protein images were used to control protein loading by quantifying the whole lane of protein bands. The membranes were transferred to polyvinylidene difluoride (PVDF) membranes (Immobilon-P). Protein bands on the blots were stained using 0.1% acetic acid. The protein images were used to control protein loading by quantifying the whole lane of protein bands.

**Results**

**Histological evaluation of osteosarcoma tissue and soft tissue callus.** A representative image of the osteosarcoma tissue from the proximal tibias of patients who had undergone amputation is shown in Fig. 1A. The white fresh tissue extruding from destructive metaphyseal was harvested. Soft callus was derived from the fracture site of donors who were treated at the Trauma Unit. Soft callus appears as soft fresh tissue covering the fracture site, as illustrated in Fig. 1B. Formalin-fixed paraffin-embedded sections of osteosarcoma tissue and soft tissue callus were stained with hematoxylin and eosin and evaluated by an experienced musculoskeletal pathologist. Histologically, the osteosarcoma tissue exhibited high cellularity and consisted of malignant plump spindle cells with osteoid matrix production (Fig. 1C). The staining of the soft callus demonstrated a high content of osteoblastic cells (Fig. 1D).

**Identification of differentially expressed proteins in osteosarcoma tissues in comparison to soft tissue callus using 2DE and LC-MS/MS.** In the protein profiling of the chemo naïve tissues derived from patients with osteosarcoma (4 cases; OS1-4) and soft tissue callus from donors (4 cases; Cal1-4), 2DE was used to analyze the protein extracted from the individual samples. The characteristics of all patients and donors are presented in Table I. The protein spots on the individual 2DE gels from the osteosarcoma tissues and soft tissue callus were matched, generating a total of 16 match sets (Fig. 2).

A total of 329 protein spots were perfectly matched between the osteosarcoma and soft callus tissues. Overall, 28 proteins were upregulated and 4 proteins were downregulated in osteosarcoma compared with soft tissue callus (±1.5-fold change, P<0.05; Fig. 3A and B). One protein spot was specifically present in the osteosarcoma tissues but not in the soft callus tissues. The differences between the volume of each protein spot in the osteosarcoma and soft tissue callus were mostly consistent among the match sets (Fig. 3C). The average fold changes of each protein spot are illustrated in Fig. 3D. All protein spots with ±1.5-fold change were cut, digested with trypsin, and subjected to LC-MS/MS analysis. The protein identification is presented in Table II.

**Enrichment analysis of GO terms of the upregulated proteins in osteosarcoma.** The WebGestalt web tool was used to determine the enriched biological processes, cellular components and molecular functions of the upregulated proteins in osteosarcoma. Of the 29 upregulated proteins, the majority were involved in metabolic processes, biological regulation, and response to stimulus (Fig. 4). Major localizations of the upregulated proteins included the secretory vesicle, nucleus, cytosol and membrane (Fig. 4). Furthermore, the majority of the observed proteins appear to have functions in protein binding (Fig. 4).

**Pathway analysis of the upregulated proteins in osteosarcoma.** To further investigate the functionally grouped networks of
Figure 1. Histology of osteosarcoma and soft callus tissues. (A) Gross specimen of an osteosarcoma mass (indicated by the black arrow). (B) Soft callus formation at the fracture site (indicated by the white arrow). (C) Hematoxylin and eosin staining of osteosarcoma and (D) soft callus tissues (magnification, x400).

Figure 2. Flow chart of the experimental design for 2DE analysis of osteosarcoma tissues and soft tissue callus. The intensity of the protein spots on individual gels was cross-matched and comparisons were made between the osteosarcoma tissue samples (OS1–4) and the soft tissue callus samples (Cal1–4). The spots of the differentially expressed proteins were digested to short peptides prior to being analyzed by LC-MS/MS. 2DE, two-dimensional electrophoresis; LC-MS/MS, liquid chromatography-tandem mass spectrometry.
Table II. Identification of differentially expressed proteins in osteosarcoma tissues compared with soft callus tissues.

| Spot no. | Accession no. | Name                        | Gene   | MW/pI | Score | Peptide match | Coverage (%) | Regulation | Fold change (mean±standard error) |
|----------|----------------|-----------------------------|--------|-------|-------|---------------|--------------|------------|----------------------------------|
| 1        | P58546         | Myotrophin                  | MTPN   | 12.89/5.27 | 71   | 3              | 14           | Up         | ↑2.76±0.28                       |
| 11       | P62937         | Peptidyl-prolyl cis-trans isomerase A, Cyclophilin | PPIA | 18.00/7.68 | 93   | 3              | 10           | Up         | ↑3.40±0.24                       |
| 14       | P30086         | Phosphatidylethanolamine-binding protein 1 | PEBP1 | 21.04/7.01 | 45   | 2              | 8            | Up         | ↑2.73±0.39                       |
| 21       | P28070         | Proteasome subunit β type-4 | PSMB4  | 29.18/5.72 | 79   | 2              | 7            | Up         | ↑1.77±0.25                       |
| 31       | P00338         | L-lactate dehydrogenase A chain | LDHA | 36.66/8.44 | 69   | 4              | 11           | Up         | ↑5.32±0.96                       |
| 34       | P04083         | Annexin A1                  | ANXA1  | 38.69/6.57 | 82   | 2              | 6            | Up         | ↑4.75±0.66                       |
| 40       | P04075         | Fructose-bisphosphate aldolase A | ALDOA | 39.40/8.30 | 71   | 5              | 11           | Up         | ↑3.40±0.58                       |
| 45       | P31930         | Cytochrome b-c1 complex subunit 1 | UQCRCl | 52.61/5.94 | 72   | 4              | 7            | Up         | ↑1.51±0.46                       |
| 51       | Q04917         | 14-3-3 protein eta | YWHAH  | 28.20/4.76 | 101  | 5              | 17           | Up         | ↑2.62±0.22                       |
| 52       | P67936         | Tropomyosin α-4 chain       | TPM4   | 28.50/4.67 | 124  | 9              | 26           | Up         | ↑1.78±0.37                       |
| 68       | P06733         | α-enolase                   | ENO1   | 47.14/7.01 | 177  | 9              | 20           | Up         | ↑2.44±0.18                       |
| 79       | Q14697         | Neutral α-glucosidase AB    | GANAB  | 106.81/5.74 | 97   | 6              | 5            | Up         | ↑4.04±0.38                       |
| 86       | P14625         | Endoplasmin                 | HSP90B1| 92.41/4.76 | 43   | 2              | 2            | Up         | ↑4.85±1.01                       |
| 87       | P31949         | Protein S100-A11            | S100A11| 31.96/5.02 | 82   | 2              | 6            | Up         | ↑3.31±0.43                       |
| 95       | P28072         | Proteasome subunit β type-6 | PSMB6  | 25.34/4.80 | 70   | 1              | 10           | Up         | ↑2.48±0.25                       |
| 102      | P09525         | Annexin A4                  | ANXA4  | 35.86/5.84 | 71   | 5              | 12           | Up         | ↑2.44±0.34                       |
| 104      | P08758         | Annexin A5                  | ANXA5  | 35.91/4.94 | 57   | 4              | 10           | Up         | ↑2.23±0.24                       |
| 107      | P47755         | F-actin-capping protein subunit α-2 | CAPZA2 | 32.93/5.57 | 74   | 3              | 10           | Up         | ↑2.08±0.32                       |
| 108      | P07195         | L-lactate dehydrogenase B chain | LDHB | 36.62/5.71 | 253  | 10             | 29           | Up         | ↑1.79±0.19                       |
| 157      | P17742         | Peptidyl-prolyl cis-trans isomerase A, Cyclophilin A | PPIA | 18.00/7.68 | 43   | 1              | 5            | Up         | ↑3.55±0.47                       |
| 299      | Q9Y3F4         | Serine-threonine kinase receptor-associated protein | STRAP | 38.41/4.98 | 69   | 5              | 14           | Up         | ↑1.91±0.25                       |
| 354      | P51157         | Ras-related protein Rab-28  | RAB28  | 24.83/5.70 | 49   | 1              | 4            | Up         | ↑2.47±0.24                       |
| 361      | P02545         | Prelamin-A/C                | LMNA   | 74.10/6.57 | 255  | 12             | 14           | Up         | ↑2.04±0.24                       |
| 372      | P10599         | Thioredoxin                 | TXN    | 11.73/4.82 | 84   | 2              | 20           | Up         | ↑2.02±0.33                       |
| 377      | P26641         | Elongation factor 1-γ       | EEF1G  | 50.09/6.25 | 51   | 3              | 5            | Up         | ↑2.99±1.17                       |
| 415      | Q9H299         | SH3 domain binding glutamic acid-rich-like protein 3 | SH3BGR1L0043/4.82 | 46 | 1 | 10 | Up | ↑1.46±0.45 | |
| 537      | P27797         | Calreticulin                | CALR   | 48.11/4.29 | 68   | 5              | 12           | Up         | ↑2.62±0.23                       |
| 583      | P11021         | 78 kDa glucose-regulated protein 1 | HSPA5 | 72.29/5.07 | 64   | 9              | 13           | Up         | ↑2.19±0.29                       |
| 613      | O75874         | Isocitrate dehydrogenase [NADP] cytoplasmic | IDH1 | 46.63/6.53 | 60   | 3              | 7            | Up         | ↑1.66±0.19                       |
| 25       | P02647         | Apolipoprotein A-I          | APOA1  | 30.76/5.56 | 147  | 10             | 32           | Down       | ↑2.00±0.33                       |
| 90       | P02766         | Transhyretin                | TTR    | 15.88/5.52 | 42   | 1              | 8            | Down       | ↑2.81±0.27                       |
| 93       | P32119         | Peroxiredoxin-2             | PRDX2  | 21.88/5.66 | 113  | 7              | 32           | Down       | ↑3.87±0.45                       |
| 634      | Q15404         | Ras suppressor protein 1    | RSU1   | 31.52/5.87 | 64   | 1              | 3            | Down       | ↑2.65±0.29                       |
| A        | P05388         | 60S acidic ribosomal protein P0 | RPLP0 | 34.25/5.71 | 48   | 1              | 3            | Present in osteosarcoma | - | |

*aProtein UniProt number; b*molecular weight (kDa) and pI from MASCOT; c*mascot score; d*number of unique peptides identified by MS/MS (multiple matches to peptides with the same primary sequence were counted as one match); e*sequence % of experimentally identified sequence peptides by tandem mass spectroscopy against unidentified sequence peptides of the same protein; and f*volume ratio of protein spot intensity in osteosarcoma relative to soft callus tissue.
upregulated proteins in osteosarcoma, the ClueGO and the CluePedia plugins of Cytoscape were used to identify the enriched pathways. ClueGO was used to integrate biological processes, molecular functions, Reactome, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and WikiPathways, and to visualize a functionally grouped network. CluePedia was used in conjunction with ClueGO for comprehensive analysis of pathways relating to protein-protein interactions and functions. With the \( \kappa \) score level set at \( \geq 0.3 \), 22 terms were found to be connected by 65 edges. Only the statistically significant (\( P<0.05 \)) enrichment terms are presented in Fig. 5A. The most significant functional groups included ‘activating transcription factor 6 (ATF6; ATF6-alpha) activates chaperone genes’, ‘phospholipase inhibitor activity’, ‘glycolysis and
Expression of important markers of the unfolded protein response (UPR) pathway is elevated in osteosarcoma cells. The results from the proteomics study demonstrated elevated levels of a number of proteins involved in the UPR pathway. The expression profiles of these proteins, including 78 kDa glucose-regulated protein (GRP78), endoplasmic (GRP94), calreticulin (ERp60) and prelamin-A/C, were validated in osteosarcoma cell lines and in the patient-derived osteosarcoma cells using western blot analysis. As illustrated in Fig. 6A, higher expression levels of GRP78, GRP94 and prelamin-A/C were observed in all osteosarcoma cell lines examined, including MNNG/HOS, 143B, U2OS, Saos-2 and MG-63, compared with the osteoblastic cells hFOB 1.19. A similar trend was also observed in the primary osteosarcoma cells; GRP78, GRP94 and prelamin-A/C were significantly upregulated in the primary osteosarcoma cells (6 cases) compared with the primary osteoblastic cells (5 cases), as illustrated in Fig. 6B. The expression levels of calreticulin were slightly altered in all of the osteosarcoma cell lines and primary cells, but these results were not as significant.

Furthermore, to examine the induction of ER stress and the UPR pathway in osteosarcoma cells, the expression levels of the spliced form of XBP1 mRNA (XBP1s) were measured using RT-qPCR and specific primers to XBP1s mRNA (22). The results demonstrated that XBP1s expression levels were significantly upregulated in most osteosarcoma cells compared with osteoblastic cells (Fig. 6C). Similar results were observed with the patient samples, with primary osteosarcoma cells exhibiting a significantly elevated expression of XBP1s compared with primary osteoblastic cells (Fig. 6D).

Association of UPR-related protein expression levels with clinical outcomes in osteosarcoma. The expression of the four identified proteins was further validated in independent sets of tissue samples that were not used in the original discovery set of the proteomics study. In addition, the expression patterns of these proteins were further investigated in osteosarcoma tissues from patients with different stages of disease, as follows: patients with stage IIB who were sensitive to chemotherapy or good responders (GR; tumor necrosis ≥90%); patients with stage IIB who responded poorly to chemotherapy (PR; tumor necrosis <90%); and patients with stage III and initial metastasis (Met). The results demonstrated that the expression of GRP94 was upregulated in the tissues of patients with non-metastasis (stage IIB) and metastasis (stage III) compared with the soft callus controls (Fig. 7A and B). Calreticulin was significantly overexpressed in the patients with stage II. Prelamin-A/C had a tendency towards overexpression in the osteosarcoma tissues. The expression of GRP78 did not differ in the patients with osteosarcoma compared with the soft callus when the patients were classified according to the Enneking staging system. Notably, by considering the expression of GRP78 protein in relation to the chemosensitivity of patients who had received the same chemotherapy regimen (DOX and platinum-based chemotherapy), the results revealed that GRP78 was markedly upregulated in the PR group compared with the soft callus and the GR groups (Fig. 7C).

Discussion
Fresh frozen tissue is the most biologically representative clinical specimen and is compatible with proteomics analysis. In the present study, upregulated proteins in biopsy tissues from patients with osteosarcoma were identified using 2DE and LC-MS/MS. Soft tissue callus was used to represent non-cancerous tissue. The formation of soft callus involves chondroblasts and osteoblasts and commonly occurs during the fracture repair process (24,25). In the present study, histological evaluation of osteoblastic morphology in the soft callus was conducted. The results revealed high osteoblastic cell content in the soft callus, suggesting that soft callus is a relevant source of osteoblasts that can represent non-cancerous tissues for proteomics study of osteosarcoma.
Figure 5. Enriched GO network groups using the ClueGo and CluePedia plugins of Cytoscape. (A) Functionally grouped networks based on GO terms, Reactome, Kyoto Encyclopedia of Genes and Genomes and WikiPathways with terms as nodes linked based on their \( \kappa \) score level (≥0.3). Only the most significant term in each group is presented using ClueGo. Associated proteins were visualized using CluePedia. (B) An overview chart with functional groups, including specific terms for the upregulated proteins in the osteosarcoma tissues. (C) GO/pathway terms specific for the upregulated proteins in the osteosarcoma tissues. The bars represent the number of genes associated with the terms. GO, gene ontology.
The results of the 2DE and LC-MS/MS in the present study revealed significant changes in the expression levels of various proteins from the osteosarcoma tissues compared with the soft callus. Using bioinformatics tools, the significantly enriched network groups identified in osteosarcoma included 'ATF6 (ATF6-alpha) activates chaperone genes', 'phospholipase inhibitor activity', 'glycolysis and gluconeogenesis', 'actin filament depolymerization' and 'substantial nigra development'. Among these functional groups, the majority of the upregulated proteins, including GRP78 (also known as BiP or HSP70 family protein 5), GRP94 (also known as heat shock protein 90 kDa β member 1) and calreticulin (also known as ERp60 or GRP60), were related to the 'ATF6 (ATF6-alpha) activates chaperone genes' group, which is one of the three major endoplasmic reticulum (ER) stress sensors controlling the UPR pathway. In addition, elevated levels of prelamin-A/C were observed, which is a protein related to the XBP1 arm of the UPR pathway. The findings from the proteomics study were further validated by investigation of the levels of these UPR-related proteins in various types of samples, including
Figure 7. Expression of UPR-related proteins in soft callus (C5-C8) and osteosarcoma tissues (OS5-OS13), including patients with stage IIB (6 cases) and stage III (3 cases) disease. (A) Western blotting of GRP78, GRP94, prelamin-A/C and calreticulin in soft callus and osteosarcoma tissues. Total proteins, used as a loading control, were evaluated using Ponceau S staining. (B) Bar graphs demonstrating the levels of the UPR-related proteins normalized to total protein in individual samples. (C and D) Quantification and statistical analysis of the levels of the tested proteins in the soft callus and osteosarcoma tissues. Data are presented as means ± standard deviation from three independent experiments. *P<0.05 compared to the soft callus, or as indicated by brackets. UPR, unfolded protein response; GRP78, 78 kDa glucose-related protein; GRP94, endoplasmin; GR, good responders; PR, poor responders; Met, metastatic; C, soft callus control; OS, osteosarcoma.
osteosarcoma cell lines, patient-derived primary cells and an independent set of tissue samples. These results substantiated the data from the proteomics study and demonstrated that all of the proteins were upregulated in osteosarcoma.

The present study revealed overexpression of three key ER chaperone proteins, including two classical UPR markers, GRP78 and GRP94, in addition to a well-characterized chaperone, calreticulin. Accumulating evidence has demonstrated that elevated expression of these proteins in a wide range of cancer types results from activation of the UPR (26). Under intrinsic perturbations and hostile environments, cancer cells restore protein homeostasis (proteostasis), which is one of the hallmarks of cancer, in order to promote cancer cell transformation and progression (27,28). The intrinsic factors include oncogenic activation, alteration in chromosome number, genomic instability, high secretion levels of proteins, and high levels of protein production (29,30). Among the extrinsic factors are hypoxia, nutrient deprivation, acidosis, altered cell metabolism, hyperproliferation and hypoglycemia (31). These factors induce ER stress, which is the result of an accumulation of misfolded proteins in the ER lumen (32). In response to ER stress, cancer cells activate the UPR, an adaptive mechanism to recover the ER protein-folding environment and proteostasis that assist cancer cell survival (31). A large amount of evidence suggests that activation of the UPR serves important roles in numerous aspects of cancer development and progression, including cell survival, angiogenesis, metastasis, resistance to treatment, adaptation, transformation and tumor dormancy (33). A diagram of the UPR pathway is provided in Fig. 8.

GRP78 is the ER master chaperone, which acts as a major regulator of the UPR (34). In non-stressed conditions, GRP78 inactivates the UPR by binding to all three ER stress inducers, PRKR-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1) and ATF6 (35). Upon ER stress, GRP78

---

Figure 8. Diagram demonstrating the unfolded protein response pathway and downstream chaperone proteins. Upwards-pointing arrows next to protein names indicate upregulated proteins in osteosarcoma. ER, endoplasmic reticulum; GRP78, 78 kDa glucose-related protein; P, phosphorylated; PERK, PRKR-like ER kinase; ATF, activating transcription factor; IRE, inositol-requiring enzyme; CHOP, C/EBP homologous protein; XBP1, X-box binding protein 1; GRP94, endoplasm; CALR, calreticulin; LMNA, lamin A/C.
activates the UPR pathways by dissociating from the stress inducers and then binding to misfolded proteins, which accumulate in the ER (Fig. 8). Free ATF6 subsequently triggers downstream signaling to increase ER protein folding capacity and ER-associated protein degradation through the transcription of various related genes that encode for the chaperone proteins, including GRP78, GRP94, calreticulin and XBP1 (34,36-38). As a consequence, during tumorigenesis, expression of GRP78 and other ER chaperones is enhanced by the UPR. Notably, Luo et al (39) demonstrated that inhibition of GRP78 upregulates ATF4 and the pro-apoptotic factor C/EBP homologous protein (CHOP) and sensitizes osteosarcoma cells to bortezomib, an FDA-approved proteasome inhibitor. Luo et al (39) also reported that upon ER stress induction, elevated expression of GRP78 protects against osteosarcoma cell death through diminishing the activity of CHOP by promoting ubiquitinating degradation of CHOP protein.

Furthermore, the present study revealed an upregulation of the spliced form of XBP1 mRNA, XBP1s, in osteosarcoma cells compared with osteoblastic cells. This finding confirmed that the ATF6 pathway was induced in osteosarcoma, because it is well known that expression of XBP1 mRNA is a downstream target of ATF6 and XBP1s (Fig. 8) (38). Significant levels of XBP1 mRNA are essential for subsequent splicing processes activated by the IRE1α-dependent pathway (40). The spliced form of XBP1 is a more stable and potent transcription activator than the un-spliced XBP1 (XBP1u). As a consequence, XBP1s effectively induces transcription of various UPR-related genes and chaperones.

Not only was GRP78 overexpressed in osteosarcoma in the present study, elevated levels of GRP78 were observed in chemo naïve tissues of patients with osteosarcoma who responded poorly to chemotherapy compared with good responders, suggesting an association of GRP78 with intrinsic drug resistance. Accumulating evidence has demonstrated an association between GRP78 and pre-existing resistance mechanisms in various types of cancer. For example, a high expression level of GRP78 in chemonaïve cancer tissues has been identified to be associated with subsequent development of chemoresistance (41,42). Furthermore, an enhanced level of GRP78 has been demonstrated to be strongly correlated with an acquired chemoresistance mechanism in cancer (43,44). Notably, Xia et al (45) demonstrated the role of GRP78 in acquired chemoresistance of osteosarcoma cell lines; DOX treatment induced P-glycoprotein (P-gp) and GRP78 expression, as well as activation of the serine/threonine kinase Akt, both in vitro and in vivo. The results also revealed an important role of GRP78 in full Akt activity, in which GRP78 activates Akt and enhances Akt-mediated P-gp expression in response to DOX treatment. In addition, DOX-resistant osteosarcoma lines that express higher levels of P-gp markedly stimulate the resistance mechanism.

Overexpression of proteins involved with the UPR pathway, particularly in the ATF6 arm, suggest that the activation of ATF6 signaling may contribute to oncosogenesis events in osteosarcoma. Schewe and Aguirre-Ghiso (46) reported a potential role of ATF6 in tumor dormancy and chemoresistance. They demonstrated that transcription factor ATF6α is an essential survival factor exclusively for quiescent cells. Silencing of the ATF6 gene reduces survival and resistance to rapamycin in dormant squamous carcinoma cells in vivo. The findings of the present study suggest that upregulation of important proteins in the ATF6 pathway may contribute to chemoresistance and tumor dormancy phenotypes in osteosarcoma cells. These findings also suggest a possible strategy for targeting UPR components for the treatment of osteosarcoma.

One of the most promising strategies is to use an agent that augments ER stress, shifting it from an adaptive to an apoptotic mechanism. Prolonged activation of UPR signals can trigger pro-apoptotic events that eliminate damaged cells. Proteasome inhibitors are key players in this respect, since the attenuation of proteasome activity effectively induces apoptosis in UPR-dependent tumors through various mechanisms (29). Prevention of proteasomal degradation results in an overwhelming accumulation of misfolded proteins in the cytosol, which induces ER stress, overcomes the UPR adaptive mechanism, and ultimately triggers apoptosis of cells. The antitumor effect of bortezomib, a FDA-approved proteasome inhibitor for the treatment of multiple myeloma, has been tested in osteosarcoma (47). Bortezomib was demonstrated to inhibit cell growth through the apoptosis pathway both in vitro and in vivo. A phase II clinical trial of bortezomib was conducted in patients with advanced or metastatic sarcoma, including adult patients with osteosarcoma (NCT00027716). Direct inhibition of GRP78 is another promising approach. In a phase I clinical trial, the GRP78 monoclonal immunoglobulin M antibody PAT-SM6 was used as a single agent in relapsed or refractory multiple myeloma (48). The results revealed that PAT-SM6 was well tolerated with modest clinical activity in the patients.

Limitations of the present study are the rarity of this type of tumor and the small number of patients. Future work will need to be performed in a larger cohort of osteosarcoma patients to validate these findings of association of UPR-related proteins and chemo-resistance.

In conclusion, the present study identified a number of pathways that are aberrantly regulated in osteosarcoma. The most significant one is an activation of the adaptive mechanism, the UPR, induced by ER stress. This finding suggests a potential role for therapeutic agents that target the UPR pathway in the treatment of osteosarcoma, inducing a shift to pro-apoptotic events and/or acting on specific key proteins.

Acknowledgements

The authors would also like to express their sincere thanks to Dr G. Lamar Robert, and Associate Professor Dr Chongchit Sripun Robert, for critical review of our manuscript, and Areerak Phanphaisarn for help with for statistical analysis. Part of this study was presented at the 9th Asia-Oceania Human Proteome Organization (AOHUPO) Conference (2018), as a poster presentation with interim findings.

Funding

This study was supported by the National Science and Technology Development Agency (grant no. P-15-50265), the Faculty of Medicine Chiang Mai University, the National Research University fund, and the Musculoskeletal Science and Translational Research Center.
Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors’ contributions

DP and PC designed the experiments. JSe performed the histological evaluation of osteosarcoma tissue and soft tissue callus. PS and PD performed the experiments in 2DE. NS performed the experiments in western blotting analysis. PT and JK performed primary cell extraction and characterization. DC performed the LC-MS/MS. PS and PT analyzed the proteomics data. PC performed network analysis, generated the data, and assembled the figures and tables. CS and JSv reviewed and edited the manuscript. DP and PC wrote the manuscript. All authors have reviewed and approved the final version of the manuscript.

Ethics approval and consent to participate

The protocol involving human clinical samples was approved by the Ethics Committee of the Faculty of Medicine, Chiang Mai University. Written informed consent was obtained from all patients.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Settakorn J, Lekawanvijit S, Arpornchayanan O, Rangdaeng S, Vanitanakom P, Kongkarnka S, Cheepsatayakorn R, Yu-In C and Thorner PS: Spectrum of bone tumors in Chiang Mai University Hospital, Thailand according to WHO classification 2002: A study of 1,001 cases. J Med Assoc Thai 89: 780-787, 2006.
2. Friebele JC, Peck J, Pan X, Abdel-Rasoul M and Mayerson JL: Osteosarcoma: A meta-analysis and review of the literature. Am J Orthop (Belle Mead NJ) 44: 547-553, 2015.
3. Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Kralio M, Anninga J, Butterfass-Bahloul T, Böhling T, Edelstein S, Gerstenfeld LC, Han W, He W, Yang W, Li J, Yang Z, Lu X, Qin A and Qian Y: The osteogenic potential of human bone callus. Sci Rep 6: 36330, 2016.
4. Srisomsap C, Sawangareetarakul P, Subthasiantop P, Pancharak M, Keggartchamnong S, Lirdprapamongkol K, Chokchaihammankit D, Sirisinha S and Svasti J: Proteomic analysis of cholangiocarcinoma cell line. Proteomics 4: 1135-1144, 2004.
5. Herosimczyk A, Dejeans N, Sayd T, Ozgo M, Krzyzpczak WD and Mazur A: Plasma proteome analysis: 2D gels and chips. J Physiol Pharmacol 57 (Suppl 7): 81-93, 2006.
6. Zhang B, Kirov S and Snoddy J: WebGestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33: W741-W748, 2005.
7. Shu Y, Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, Lindon J, Sneddon R and Linsley PS: Overexpression of CD99 and CD59 in cultured osteosarcoma cells is a major source of soft callus in bone fracture. J Bone Miner Metab 31: 90-91, 2013.
8. Watanabe K, Okamoto K and Yonehara S: Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 12: 10-18, 2005.
9. Beattie BS, Kondratenko K, Kosikina NV, Stewart J and Kleinerman ES: The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets 13: 411-422, 2013.
10. Zhou S, Denman C, Cobanoglu ZS, Xiany S, Lau CC, Gottschalk SM, Hughes DP, Kleinerman ES and Lee DA: The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res 32: 779-792, 2015.
11. Hu Y, Liang Q, Wen YJ, Chen LL, Wang LT, Liu YL, Luo CQ, Liang HZ, Li MT and Li Z: Comparative proteomics analysis of human osteosarcomas and benign tumor of bone. Cancer Genet Cytogenet 198: 97-106, 2010.
12. Rao UN, Hood BL, Jones-Laughner JM, Sun M and Conrads TP: Distinct profiles of oxidative stress-related and matrix proteins in adult bone and soft tissue osteosarcoma and dendritic tumors: A proteomics study. Hum Pathol 44: 725-733, 2013.
13. Einhorn TA and Gerstenfeld LC: Fracture healing: Mechanisms and interventions. Nat Rev Rheumatol 11: 45-54, 2015.
14. Murao H, Yamamoto K, Matsuda S and Akiyama H: Periosteal cells are a major source of soft callus in bone fracture. J Bone Miner Metab 31: 390-398, 2013.
15. Han W, He W, Yang W, Li J, Yang Z, Lu X, Qin A and Qian Y: The osteogenic potential of human bone callus. Sci Rep 6: 36330, 2016.
16. Srisomsap C, Sawangareetarakul P, Subthasiantop P, Pancharak M, Keggartchamnong S, Lirdprapamongkol K, Chokchaihammankit D, Sirisinha S and Svasti J: Proteomic analysis of cholangiocarcinoma cell line. Proteomics 4: 1135-1144, 2004.
17. Herosimczyk A, Dejeans N, Sayd T, Ozgo M, Krzyzpczak WD and Mazur A: Plasma proteome analysis: 2D gels and chips. J Physiol Pharmacol 57 (Suppl 7): 81-93, 2006.
18. Zhang B, Kirov S and Snoddy J: WebGestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33: W741-W748, 2005.
19. Shu Y, Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, Lindon J, Sneddon R and Linsley PS: Overexpression of CD99 and CD59 in cultured osteosarcoma cells is a major source of soft callus in bone fracture. J Bone Miner Metab 31: 90-91, 2013.
20. van Schadewijk A, van’t Wout EF, Stolk J and Hiemstra PS: A quantitative method for detection of spliced X-box binding protein-1 (XBP1) mRNA as a measure of endoplasmic reticulum (ER) stress. Cell Stress Chaperones 17: 275-279, 2012.
21. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2( -Delta Delta C(T)) method. Methods 25: 402-408, 2001.
22. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2( -Delta Delta C(T)) method. Methods 25: 402-408, 2001.
23. Schindeler A, McDonald MM, Bokko P and Little DG: Bone morphogenesis: A quantitative method for detection of spliced X-box binding protein-1 (XBP1) mRNA as a measure of endoplasmic reticulum (ER) stress. Cell Stress Chaperones 17: 275-279, 2012.
24. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2( -Delta Delta C(T)) method. Methods 25: 402-408, 2001.
25. Schindeler A, McDonald MM, Bokko P and Little DG: Bone morphogenesis: A quantitative method for detection of spliced X-box binding protein-1 (XBP1) mRNA as a measure of endoplasmic reticulum (ER) stress. Cell Stress Chaperones 17: 275-279, 2012.
26. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2( -Delta Delta C(T)) method. Methods 25: 402-408, 2001.
27. Schindeler A, McDonald MM, Bokko P and Little DG: Bone morphogenesis: A quantitative method for detection of spliced X-box binding protein-1 (XBP1) mRNA as a measure of endoplasmic reticulum (ER) stress. Cell Stress Chaperones 17: 275-279, 2012.
31. Ma Y and Hendershot LM: The role of the unfolded protein response in tumour development: Friend or foe? Nat Rev Cancer 4: 966-977, 2004.
32. Hetz C: The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 13: 89-102, 2012.
33. Dufey E, Urba H and Hetz C: ER proteostasis addiction in cancer biology: Novel concepts. Semin Cancer Biol 33: 40-47, 2015.
34. Lee AS: Glucose-regulated proteins in cancer: Molecular mechanisms and therapeutic potential. Nat Rev Cancer 14: 263-276, 2014.
35. Wang M, Wey S, Zhang Y, Ye R and Lee AS: Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. Antioxid Redox Signal 11: 2307-2316, 2009.
36. Chang SC, Erwin AE and Lee AS: Glucose-regulated protein (GRP94 and GRP78) genes share common regulatory domains and are coordinately regulated by common trans-acting factors. Mol Cell Biol 9: 2153-2162, 1989.
37. Yamamoto K, Sato T, Matsui T, Sato M, Okada T, Yoshida H, Harada A and Mori K: Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. Dev Cell 13: 365-376, 2007.
38. Yoshida H, Matsui T, Yamamoto A, Okada T and Mori K: XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107: 881-891, 2001.
39. Luo J, Xia Y, Luo J, Li J, Zhang C, Zhang H, Ma T, Yang L and Kong L: GRP78 inhibition enhances ATF4-induced cell death by the deubiquitination and stabilization of CHOP in human osteosarcoma. Cancer Lett 410: 112-123, 2017.
40. Lee K, Tiraspomon W, Shen X, Michalak M, Prywes R, Okada T, Yoshida H, Mori K and Kaufman RJ: IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev 16: 452-466, 2002.
41. Lee E, Nichols P, Spicer D, Groshen S, Yu MC and Lee AS: GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 66: 7849-7853, 2006.
42. Mhaidat NM, Alzoubi KH, Almomani N and Khoury OF: Expression of glucose regulated protein 78 (GRP78) determines colorectal cancer response to chemotherapy. Cancer Biomark 15: 197-203, 2015.
43. Gifford JB, Huang W, Zeleniak AE, Hindoyan A, Wu H, Donahue TR and Hill R: Expression of GRP78, master regulator of the unfolded protein response, increases chemoresistance in pancreatic ductal adenocarcinoma. Mol Cancer Ther 15: 1043-1052, 2016.
44. Li W, Wang W, Dong H, Li Y, Li L, Han L, Han Z, Wang S, Ma D and Wang H: Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78. Oncol Rep 31: 2525-2534, 2014.
45. Xia YZ, Yang L, Xue GM, Zhang C, Guo C, Yang YW, Li SS, Zhang LY, Guo QL and Kong LY: Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma. Oncotarget 7: 56371-56382, 2016.
46. Schewe DM and Aguirre-Ghiso JA: ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc Natl Acad Sci USA 105: 10519-10524, 2008.
47. Shapovalov Y, Benavidez D, Zuch D and Eliseev RA: Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. Int J Cancer 127: 67-76, 2010.
48. Rasche L, Duell J, Castro IC, Dubiljevic V, Chatterjee M, Knop S, Hensel F, Rosenwald A, Einsele H, Topp MS, et al: GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. Haematologica 100: 377-384, 2015.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.